Literature DB >> 21079159

Neck dissection after chemoradiotherapy: timing and complications.

Laura A Goguen1, Claudia I Chapuy, Yi Li, Sihai D Zhao, Donald J Annino.   

Abstract

OBJECTIVES: To determine the incidence of postchemoradiotherapy (post-CRT) neck dissection (ND) complications; to ascertain whether timing (< 12 vs ≥ 12 weeks) from CRT to ND or other factors are associated with increased complications; and to determine whether ND timing influences disease control or survival.
DESIGN: Ten-year retrospective analysis.
SETTING: Tertiary care center. PATIENTS: One hundred five patients with head and neck cancer undergoing ND after CRT. MAIN OUTCOME MEASURES: Complications and survival variables compared between groups undergoing ND less than 12 weeks (less-than-12-weeks ND group) and 12 weeks or more (12-weeks-or-more ND group) after CRT.
RESULTS: Sixty-seven NDs were performed less than 12 weeks and 38 were performed 12 weeks or more after CRT. Patient characteristics, treatment, and ND pathology results were comparable between the 2 ND groups. The incidence of complications between the less-than-12-weeks and the 12-weeks-or-more ND groups included major wound complications in 8 of 67 (11.9%) vs 1 of 38 (2.6%; P = .15), minor wound complications in 11 of 67 (16.4%) vs 4 of 38 (10.5%; P = .56), airway complications in 7 of 67 (10.4%) vs 2 of 38 (5.3%; P = .48), and systemic complications in 9 of 67 (13.4%) vs 2 of 38 (5.3%; P = .32). The number of patients with at least 1 complication was significantly smaller in the 12-weeks-or-more ND group (P = .04). Multivariate analysis showed that radical ND was significantly associated with an increased number of complications, and higher radiation doses approached significance (P = .05). Induction chemotherapy was associated with fewer wound complications (P = .01). There were no significant differences in overall survival (P = .82), progression-free survival (P = .77), or regional relapse (P = .54) between groups. Positive ND findings were associated with diminished progression-free and overall survival.
CONCLUSION: These findings indicate that ND can be safely performed 12 weeks or more after CRT without adversely affecting surgical complications or survival variables.

Entities:  

Mesh:

Year:  2010        PMID: 21079159     DOI: 10.1001/archoto.2010.188

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  10 in total

1.  Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors.

Authors:  Claudia I Chapuy; Donald J Annino; Anna Snavely; Yi Li; Roy B Tishler; Charles M Norris; Robert I Haddad; Laura A Goguen
Journal:  Otolaryngol Head Neck Surg       Date:  2011-09       Impact factor: 3.497

2.  Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

Authors:  R Montal; M Oliva; M Taberna; L De Avila; A Rovira; M Cos; M Mañós; V Navarro; J Nogués; A Lozano; L Rodríguez; E Vilajosana; S Vázquez; R Mesia
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

3.  Quantitative ultrasound delta-radiomics during radiotherapy for monitoring treatment responses in head and neck malignancies.

Authors:  William T Tran; Harini Suraweera; Karina Quiaoit; Daniel DiCenzo; Kashuf Fatima; Deok Jang; Divya Bhardwaj; Christopher Kolios; Irene Karam; Ian Poon; Lakshmanan Sannachi; Mehrdad Gangeh; Ali Sadeghi-Naini; Archya Dasgupta; Gregory J Czarnota
Journal:  Future Sci OA       Date:  2020-09-04

Review 4.  Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma.

Authors:  H Hakan Coskun; Jesus E Medina; K Thomas Robbins; Carl E Silver; Primož Strojan; Afshin Teymoortash; Phillip K Pellitteri; Juan P Rodrigo; Sandro J Stoeckli; Ashok R Shaha; Carlos Suárez; Dana M Hartl; Remco de Bree; Robert P Takes; Marc Hamoir; Karen T Pitman; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2014-06-30       Impact factor: 3.147

5.  Time interval between primary radiotherapy and salvage laryngectomy: a predictor of pharyngocutaneous fistula formation.

Authors:  William J Scotton; I J Nixon; T F Pezier; R Cobb; A Joshi; T Guerrero Urbano; R Oakley; J P Jeannon; R S Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-17       Impact factor: 2.503

6.  Predictive factors for postoperative wound complications after neck dissection.

Authors:  R Pellini; G Mercante; C Marchese; V Terenzi; I Sperduti; V Manciocco; P Ruscito; G Cristalli; P Marchesi; B Pichi; G Spriano
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

7.  18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy.

Authors:  Nils Helsen; Dessie Roothans; Bert Van Den Heuvel; Tim Van den Wyngaert; Danielle Van den Weyngaert; Laurens Carp; Sigrid Stroobants
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

8.  Predictive quantitative ultrasound radiomic markers associated with treatment response in head and neck cancer.

Authors:  William T Tran; Harini Suraweera; Karina Quaioit; Daniel Cardenas; Kai X Leong; Irene Karam; Ian Poon; Deok Jang; Lakshmanan Sannachi; Mehrdad Gangeh; Sami Tabbarah; Andrew Lagree; Ali Sadeghi-Naini; Gregory J Czarnota
Journal:  Future Sci OA       Date:  2019-11-26

Review 9.  Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review.

Authors:  L Putten; R Bree; P A Doornaert; J Buter; S E J Eerenstein; D H F Rietveld; D J Kuik; C R Leemans
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-06       Impact factor: 2.124

10.  Complete pathologic response as a prognostic factor for squamous cell carcinoma of the oropharynx post-chemoradiotherapy.

Authors:  Damila Cristina Trufelli; Leandro Luongo de Matos; Thaiana Aragão Santana; Fábio de Aquino Capelli; Jossi Ledo Kanda; Auro Del Giglio; Gilberto de Castro Junior
Journal:  Braz J Otorhinolaryngol       Date:  2015-07-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.